NASDAQ:HRTX - Heron Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$31.45 +0.55 (+1.78 %)
(As of 05/27/2018 07:43 AM ET)
Previous Close$31.45
Today's Range$30.80 - $31.95
52-Week Range$12.70 - $34.00
Volume756,982 shs
Average Volume920,522 shs
Market Capitalization$2.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.88

About Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics logoHeron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, a neurokinin-1 receptor antagonist aprepitant for the prevention of CINV; and HTX-011, which is in Phase III clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HRTX
CUSIPN/A
Phone858-251-4400

Debt

Debt-to-Equity RatioN/A
Current Ratio1.94
Quick Ratio1.72

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$30.77 million
Price / Sales73.54
Cash Flow$3.0894 per share
Price / Cash10.18
Book Value$1.28 per share
Price / Book24.57

Profitability

EPS (Most Recent Fiscal Year)$3.65
Net Income$-197,480,000.00
Net Margins-515.27%
Return on Equity-239.94%
Return on Assets-117.61%

Miscellaneous

Employees145
Outstanding Shares71,950,000

Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics (NASDAQ:HRTX) released its earnings results on Thursday, May, 10th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.87) by $0.06. The biotechnology company had revenue of $11.60 million for the quarter, compared to analysts' expectations of $11.10 million. Heron Therapeutics had a negative net margin of 515.27% and a negative return on equity of 239.94%. Heron Therapeutics's quarterly revenue was up 222.2% compared to the same quarter last year. View Heron Therapeutics' Earnings History.

What price target have analysts set for HRTX?

12 equities research analysts have issued 12 month price targets for Heron Therapeutics' stock. Their predictions range from $22.00 to $56.00. On average, they expect Heron Therapeutics' stock price to reach $38.0833 in the next year. View Analyst Ratings for Heron Therapeutics.

What are Wall Street analysts saying about Heron Therapeutics stock?

Here are some recent quotes from research analysts about Heron Therapeutics stock:
  • 1. Cowen Inc analysts commented, "We are still waiting to speak with the company and have thus not yet updated our model and price target, but do not recommend buying on weakness." (3/19/2018)
  • 2. Mizuho analysts commented, "We believe the results demonstrate the superior product profile of HTX-011 in post-operative pain management compared to the current standard of care. We raise our PT from $28 to $35." (3/19/2018)
  • 3. Cantor Fitzgerald analysts commented, "Late Friday, Jan. 12, Tesaro (Not Covered) announced that it had modified the Warnings section of the package insert for Varubi to include post-marketing reports of anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions, some requiring hospitalization." (1/15/2018)
  • 4. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (1/10/2018)

Who are some of Heron Therapeutics' key competitors?

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the folowing people:
  • Dr. Barry D. Quart, Chief Exec. Officer and Director (Age 61)
  • Mr. Robert H. Rosen, Pres and Director (Age 62)
  • Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 58)
  • Mr. Robert E. Hoffman CPA, Chief Financial Officer and Sr. VP of Fin. (Age 52)
  • Mr. David L. Szekeres, Sr. VP - Bus. Devel., Gen. Counsel & Corp. Sec. (Age 44)

Has Heron Therapeutics been receiving favorable news coverage?

Media coverage about HRTX stock has trended positive on Sunday, according to Accern Sentiment. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Heron Therapeutics earned a news impact score of 0.42 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.47 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Tang Capital Management LLC (12.02%), Franklin Resources Inc. (9.79%), BlackRock Inc. (4.88%), Eagle Asset Management Inc. (2.52%), Rubric Capital Management LP (2.10%) and Highland Capital Management LP (2.07%). Company insiders that own Heron Therapeutics stock include Barry D Quart, Kevin C Tang, Kimberly Manhard and Robert Rosen. View Institutional Ownership Trends for Heron Therapeutics.

Which institutional investors are selling Heron Therapeutics stock?

HRTX stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Rubric Capital Management LP, JPMorgan Chase & Co., Asymmetry Capital Management L.P., C WorldWide Group Holding A S, Fisher Asset Management LLC, Old West Investment Management LLC and Great West Life Assurance Co. Can. Company insiders that have sold Heron Therapeutics company stock in the last year include Barry D Quart and Kimberly Manhard. View Insider Buying and Selling for Heron Therapeutics.

Which institutional investors are buying Heron Therapeutics stock?

HRTX stock was purchased by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., BlackRock Inc., Nexthera Capital LP, Rock Springs Capital Management LP, Tang Capital Management LLC, UBS Group AG and Cohen Capital Management Inc.. View Insider Buying and Selling for Heron Therapeutics.

How do I buy shares of Heron Therapeutics?

Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $31.45.

How big of a company is Heron Therapeutics?

Heron Therapeutics has a market capitalization of $2.26 billion and generates $30.77 million in revenue each year. The biotechnology company earns $-197,480,000.00 in net income (profit) each year or $3.65 on an earnings per share basis. Heron Therapeutics employs 145 workers across the globe.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]


MarketBeat Community Rating for Heron Therapeutics (HRTX)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  416 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  597
MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote "Outperform" if you believe HRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Heron Therapeutics (NASDAQ:HRTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for Heron Therapeutics in the last 12 months. Their average twelve-month price target is $38.0833, suggesting that the stock has a possible upside of 21.09%. The high price target for HRTX is $56.00 and the low price target for HRTX is $22.00. There are currently 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.0833$37.4167$31.00$29.80
Price Target Upside: 21.09% upside20.12% upside29.71% upside82.26% upside

Heron Therapeutics (NASDAQ:HRTX) Consensus Price Target History

Price Target History for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ:HRTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2018Cantor FitzgeraldSet Price TargetBuy$40.00MediumView Rating Details
5/10/2018OppenheimerSet Price TargetBuy$34.00HighView Rating Details
5/8/2018CowenReiterated RatingBuy$48.00LowView Rating Details
4/5/2018Evercore ISIInitiated CoverageOutperform$56.00MediumView Rating Details
4/5/2018Lake Street CapitalSet Price TargetBuy$42.00MediumView Rating Details
3/26/2018Northland SecuritiesReiterated RatingBuy$55.00LowView Rating Details
3/21/2018Noble FinancialReiterated RatingBuyLowView Rating Details
3/20/2018Needham & Company LLCBoost Price TargetBuy$42.00MediumView Rating Details
3/19/2018MizuhoReiterated RatingBuy ➝ Buy$28.00 ➝ $35.00HighView Rating Details
1/2/2018Leerink SwannInitiated CoverageOutperform ➝ Outperform$22.00HighView Rating Details
8/16/2017Jefferies GroupReiterated RatingBuyLowView Rating Details
7/18/2017AegisReiterated RatingBuy$33.00LowView Rating Details
11/9/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$41.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Heron Therapeutics (NASDAQ:HRTX) Earnings History and Estimates Chart

Earnings by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ:HRTX) Earnings Estimates

2018 EPS Consensus Estimate: ($2.39)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.86)($0.69)($0.75)
Q2 20183($0.70)($0.64)($0.66)
Q3 20183($0.69)($0.36)($0.53)
Q4 20183($0.71)($0.25)($0.45)

Heron Therapeutics (NASDAQ HRTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/20183/31/2018($0.87)($0.81)$11.10 million$11.60 millionViewN/AView Earnings Details
2/27/2018Q4 2017($0.7950)($1.09)$9.00 million$10.05 millionViewN/AView Earnings Details
11/6/2017Q3 2017($0.87)($0.77)$8.12 million$8.57 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.8990)($0.80)$4.53 million$8.51 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.9380)($1.00)$1.96 million$3.63 millionViewN/AView Earnings Details
2/23/2017Q4 2016($1.17)($1.22)$1.07 million$1.28 millionViewN/AView Earnings Details
11/8/2016Q3 2016($1.17)($1.24)ViewN/AView Earnings Details
8/8/2016Q2($0.96)($1.17)ViewN/AView Earnings Details
5/5/2016Q1($0.92)($0.92)ViewN/AView Earnings Details
2/19/2016Q4($0.6370)($0.87)ViewN/AView Earnings Details
11/6/2015Q3($0.67)($0.63)ViewN/AView Earnings Details
8/7/2015Q2 2015($0.65)($0.74)ViewN/AView Earnings Details
5/8/2015Q115($0.64)($0.70)ViewN/AView Earnings Details
3/13/2015Q4 2014($0.69)($0.71)ViewN/AView Earnings Details
11/6/2014Q3 2014($0.69)($0.66)ViewN/AView Earnings Details
8/4/2014Q2 2014($0.62)($0.78)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.58)($0.74)ViewN/AView Earnings Details
3/5/2014($0.53)($0.75)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.80)($0.80)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.80)($1.00)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.60)($0.80)ViewN/AView Earnings Details
3/1/2013Q4 2012($0.40)($0.60)ViewN/AView Earnings Details
11/5/2012Q3 2012($0.20)($0.40)ViewN/AView Earnings Details
8/2/2012Q2 2012($0.40)($0.40)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.40)ViewN/AView Earnings Details
11/7/2011Q3 2011($0.42)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.94)ViewN/AView Earnings Details
5/16/2011Q1 2011($0.66)ViewN/AView Earnings Details
3/28/2011Q4 2010($0.76)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.82)ViewN/AView Earnings Details
8/16/2010Q2 2010($1.88)ViewN/AView Earnings Details
5/17/2010Q1 2010($1.46)ViewN/AView Earnings Details
3/15/2010Q4 2009($1.22)ViewN/AView Earnings Details
11/16/2009Q3 2009($0.80)ViewN/AView Earnings Details
8/4/2009Q2 2009($2.54)ViewN/AView Earnings Details
5/14/2009Q1 2009($2.00)($1.92)ViewN/AView Earnings Details
3/31/2009Q4 2008($4.00)($2.50)ViewN/AView Earnings Details
11/5/2008Q3 2008($4.40)($4.02)ViewN/AView Earnings Details
8/14/2008Q2 2008($3.98)ViewN/AView Earnings Details
5/15/2008Q1 2008($4.44)ViewN/AView Earnings Details
3/13/2008Q4 2007($3.80)($5.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Heron Therapeutics (NASDAQ:HRTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Heron Therapeutics (NASDAQ HRTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.93%
Insider Trading History for Heron Therapeutics (NASDAQ:HRTX)
Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ HRTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/29/2018Kevin C TangDirectorBuy192,308$26.00$5,000,008.00View SEC Filing  
3/19/2018Barry D QuartCEOSell100,000$29.75$2,975,000.00167,993View SEC Filing  
3/19/2018Kimberly ManhardVPSell18,000$30.00$540,000.0018,000View SEC Filing  
3/14/2018Barry D QuartCEOSell100,000$24.75$2,475,000.00167,993View SEC Filing  
1/10/2018Kimberly ManhardVPSell7,584$20.00$151,680.007,584View SEC Filing  
4/24/2017Kimberly ManhardVPSell21,542$15.33$330,238.865,250View SEC Filing  
1/19/2017Kevin C TangDirectorBuy2,459,016$12.20$29,999,995.20View SEC Filing  
8/10/2016Robert RosenInsiderSell100,000$23.30$2,330,000.00102,640View SEC Filing  
4/21/2016Robert RosenPresidentSell200,000$23.23$4,646,000.00178,968View SEC Filing  
6/10/2015Kevin C TangDirectorBuy121,212$24.75$2,999,997.00View SEC Filing  
6/2/2015Kevin C TangDirectorBuy150,000$20.62$3,093,000.00View SEC Filing  
6/1/2015Kimberly ManhardDirectorSell2,708$21.17$57,328.36View SEC Filing  
6/25/2014Barry D QuartCEOBuy10,000$11.75$117,500.00View SEC Filing  
6/25/2014Kevin C TangDirectorBuy510,638$11.75$5,999,996.50View SEC Filing  
11/20/2013Barry D QuartCEOBuy1,000,000$0.40$400,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Heron Therapeutics (NASDAQ HRTX) News Headlines

Source:
DateHeadline
Cantor Fitzgerald Analysts Give Heron Therapeutics (HRTX) a $40.00 Price TargetCantor Fitzgerald Analysts Give Heron Therapeutics (HRTX) a $40.00 Price Target
www.americanbankingnews.com - May 24 at 4:23 PM
Heron Therapeutics (HRTX) Receives Average Rating of "Buy" from BrokeragesHeron Therapeutics (HRTX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 24 at 3:22 PM
Cantor Fitzgerald Weighs in on Heron Therapeutics FY2018 Earnings (HRTX)Cantor Fitzgerald Weighs in on Heron Therapeutics' FY2018 Earnings (HRTX)
www.americanbankingnews.com - May 24 at 8:36 AM
Heron Therapeutics (HRTX) Expected to Post Quarterly Sales of $13.79 MillionHeron Therapeutics (HRTX) Expected to Post Quarterly Sales of $13.79 Million
www.americanbankingnews.com - May 20 at 4:41 AM
Heron Therapeutics (HRTX) Upgraded to Buy at BidaskClubHeron Therapeutics (HRTX) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - May 19 at 11:03 AM
Heron Therapeutics (HRTX) Stock Rating Lowered by BidaskClubHeron Therapeutics (HRTX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - May 11 at 8:05 PM
Heron Therapeutics (HRTX) Given a $34.00 Price Target by Oppenheimer AnalystsHeron Therapeutics (HRTX) Given a $34.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - May 10 at 7:03 PM
Heron Therapeutics (HRTX) Announces Quarterly  Earnings ResultsHeron Therapeutics (HRTX) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 5:47 PM
Heron Therapeutics beats by $0.05, beats on revenueHeron Therapeutics beats by $0.05, beats on revenue
seekingalpha.com - May 10 at 9:15 AM
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate ProgressHeron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress
finance.yahoo.com - May 10 at 9:15 AM
Heron Therapeutics: 1Q Earnings SnapshotHeron Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 9:15 AM
Heron Therapeutics to Present at the Bank of America Merrill Lynch 2018 Healthcare ConferenceHeron Therapeutics to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
finance.yahoo.com - May 9 at 4:51 PM
Cowen Reaffirms Buy Rating for Heron Therapeutics (HRTX)Cowen Reaffirms Buy Rating for Heron Therapeutics (HRTX)
www.americanbankingnews.com - May 8 at 4:40 PM
Don't Waste Your Money On Penny Stocks -- These 3 Stocks Are Better BuysDon't Waste Your Money On Penny Stocks -- These 3 Stocks Are Better Buys
finance.yahoo.com - May 2 at 8:55 AM
$11.26 Million in Sales Expected for Heron Therapeutics (HRTX) This Quarter$11.26 Million in Sales Expected for Heron Therapeutics (HRTX) This Quarter
www.americanbankingnews.com - May 2 at 2:22 AM
Heron Therapeutics (HRTX) Expected to Post Earnings of -$0.82 Per ShareHeron Therapeutics (HRTX) Expected to Post Earnings of -$0.82 Per Share
www.americanbankingnews.com - April 30 at 5:14 PM
Heron Therapeutics (HRTX) Receives Average Rating of "Buy" from AnalystsHeron Therapeutics (HRTX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 29 at 5:59 PM
Heron Therapeutics: Clear Path To Approval For HTX-011Heron Therapeutics: Clear Path To Approval For HTX-011
seekingalpha.com - April 29 at 9:04 AM
Opinion: Harry Boxers two biotechnology stocks to watch todayOpinion: Harry Boxer's two biotechnology stocks to watch today
www.marketwatch.com - April 26 at 4:48 PM
Harry Boxer’s two biotechnology stocks to watch todayHarry Boxer’s two biotechnology stocks to watch today
finance.yahoo.com - April 26 at 4:48 PM
Heron Therapeutics (HRTX) PT Set at $40.00 by Cantor FitzgeraldHeron Therapeutics (HRTX) PT Set at $40.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 23 at 9:48 AM
Heron Therapeutics (HRTX) Overweight Rating Reaffirmed at Cantor FitzgeraldHeron Therapeutics' (HRTX) Overweight Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - April 20 at 4:17 PM
Heron Therapeutics (HRTX) Upgraded at Zacks Investment ResearchHeron Therapeutics (HRTX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 18 at 11:54 PM
Brokers Issue Forecasts for Heron Therapeutics Q1 2018 Earnings (HRTX)Brokers Issue Forecasts for Heron Therapeutics' Q1 2018 Earnings (HRTX)
www.americanbankingnews.com - April 18 at 7:54 AM
Heron Therapeutics (HRTX) Given Buy Rating at AegisHeron Therapeutics (HRTX) Given Buy Rating at Aegis
www.americanbankingnews.com - April 17 at 5:25 PM
Heron Therapeutics (HRTX) Expected to Announce Quarterly Sales of $10.96 MillionHeron Therapeutics (HRTX) Expected to Announce Quarterly Sales of $10.96 Million
www.americanbankingnews.com - April 15 at 2:30 AM
Zacks: Analysts Expect Heron Therapeutics Inc (HRTX) to Announce -$0.82 Earnings Per ShareZacks: Analysts Expect Heron Therapeutics Inc (HRTX) to Announce -$0.82 Earnings Per Share
www.americanbankingnews.com - April 13 at 7:15 PM
July 20th Options Now Available For Heron Therapeutics (HRTX)July 20th Options Now Available For Heron Therapeutics (HRTX)
www.nasdaq.com - April 13 at 4:51 PM
An Intrinsic Calculation For Heron Therapeutics Inc (NASDAQ:HRTX) Shows It’s 36% UndervaluedAn Intrinsic Calculation For Heron Therapeutics Inc (NASDAQ:HRTX) Shows It’s 36% Undervalued
finance.yahoo.com - April 12 at 9:52 AM
Pre-Open Movers 04/05: (CHFS) (FNSR) (HRTX) Higher; (CNAT) (CHECK) (CONN) Lower (more...)Pre-Open Movers 04/05: (CHFS) (FNSR) (HRTX) Higher; (CNAT) (CHECK) (CONN) Lower (more...)
www.streetinsider.com - April 5 at 4:49 PM
Evercore ISI Initiates Coverage on Heron Therapeutics (HRTX)Evercore ISI Initiates Coverage on Heron Therapeutics (HRTX)
www.americanbankingnews.com - April 5 at 2:09 PM
Lake Street Capital Analysts Give Heron Therapeutics (HRTX) a $42.00 Price TargetLake Street Capital Analysts Give Heron Therapeutics (HRTX) a $42.00 Price Target
www.americanbankingnews.com - April 5 at 2:08 PM
Heron Therapeutics Announces Pricing of Underwritten Public Offering of Common StockHeron Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
finance.yahoo.com - April 5 at 9:32 AM
Cantor Fitzgerald Analysts Give Heron Therapeutics (HRTX) a $31.00 Price TargetCantor Fitzgerald Analysts Give Heron Therapeutics (HRTX) a $31.00 Price Target
www.americanbankingnews.com - April 4 at 7:58 PM
Heron Therapeutics Inc (HRTX) Receives Consensus Rating of "Buy" from BrokeragesHeron Therapeutics Inc (HRTX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 4 at 5:52 PM
Heron Therapeutics Target of Unusually High Options Trading (HRTX)Heron Therapeutics Target of Unusually High Options Trading (HRTX)
www.americanbankingnews.com - April 4 at 7:58 AM
Financial Contrast: Hutchison China MediTech (HCM) versus Heron Therapeutics (HRTX)Financial Contrast: Hutchison China MediTech (HCM) versus Heron Therapeutics (HRTX)
www.americanbankingnews.com - April 4 at 7:07 AM
Heron Therapeutics (HRTX) Upgraded at ValuEngineHeron Therapeutics (HRTX) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 1:54 PM
Heron Therapeutics Inc (HRTX) Director Buys $5,000,008.00 in StockHeron Therapeutics Inc (HRTX) Director Buys $5,000,008.00 in Stock
www.americanbankingnews.com - April 2 at 4:14 PM
Heron Therapeutics (HRTX) Buy Rating Reaffirmed at Cantor FitzgeraldHeron Therapeutics' (HRTX) Buy Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - April 1 at 11:24 PM
Heron Therapeutics (HRTX) Receives Buy Rating from MizuhoHeron Therapeutics (HRTX) Receives Buy Rating from Mizuho
www.americanbankingnews.com - April 1 at 2:38 PM
Heron Is A Solid Long-Term InvestmentHeron Is A Solid Long-Term Investment
seekingalpha.com - March 30 at 4:54 PM
Your Daily Pharma Scoop: Heron Offering, Sorrento Issues Letter To Shareholders, MediciNova SetbackYour Daily Pharma Scoop: Heron Offering, Sorrento Issues Letter To Shareholders, MediciNova Setback
seekingalpha.com - March 30 at 9:04 AM
Zacks Investment Research Downgrades Heron Therapeutics (HRTX) to HoldZacks Investment Research Downgrades Heron Therapeutics (HRTX) to Hold
www.americanbankingnews.com - March 29 at 7:58 PM
Heron Therapeutics down 4% premarket on pricing common stock offeringHeron Therapeutics down 4% premarket on pricing common stock offering
seekingalpha.com - March 29 at 9:20 AM
$10.96 Million in Sales Expected for Heron Therapeutics Inc (HRTX) This Quarter$10.96 Million in Sales Expected for Heron Therapeutics Inc (HRTX) This Quarter
www.americanbankingnews.com - March 29 at 2:30 AM
Heron Therapeutics Announces Proposed Public Offering of Common StockHeron Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 28 at 4:46 PM
Heron Therapeutics (HRTX) Buy Rating Reaffirmed at MizuhoHeron Therapeutics' (HRTX) Buy Rating Reaffirmed at Mizuho
www.americanbankingnews.com - March 28 at 12:58 PM
Heron Therapeutics (HRTX) Buy Rating Reiterated at Northland SecuritiesHeron Therapeutics' (HRTX) Buy Rating Reiterated at Northland Securities
www.americanbankingnews.com - March 26 at 1:24 PM
Heron Therapeutics (HRTX) Lowered to "Hold" at BidaskClubHeron Therapeutics (HRTX) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - March 26 at 8:39 AM

SEC Filings

Heron Therapeutics (NASDAQ:HRTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Heron Therapeutics (NASDAQ:HRTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Heron Therapeutics (NASDAQ HRTX) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.